Sapient

#Gratitude ???? ????????????: Thanksgiving is a time of year to embrace the spirit of gratitude and generosity. We held our own "Teams-giving" to celebrate both, complete with a canned food drive to benefit the Jacobs & Cushman San Diego Food Bank. We split into two teams – Team Peas?? and Team Carrots?? – for a contest to see who could deliver the most donations. While the competition was fierce, it was ultimately our community that won, with donations far exceeding expectations and over 1,500 ???????????? of canned goods ultimately collected between our teams! The dedication of every individual to making this drive a success, to make the holidays brighter for families in need, is a testament to why we're thankful for the #SapientTeam! We wish you a very ?????????? ???????????????????????? and the time to spend with your loved ones doing the things that make you most grateful.

A new study review by Science (AAAS) illuminates the potential scale and biological impact of the "dark proteome", providing a more complete picture of the coding portion of the human genome that goes well beyond the 20,000 genes described today. https://lnkd.in/g93qfKag ? By traditional definition, a #gene consists of a long DNA sequence with?an open reading frame (OFR) that is transcribed to encode a protein with 100 or more amino acids. But it is becoming clear that hundreds or even thousands of non-canonical proteins may exist. These include?shorter "miniproteins" that are translated from non-canonical open reading frames (ncORFs), as well as aberrant?splice isoforms, frameshift isoforms, mutant variant proteins, and proteins with non-canonical post-translational modifications. While initially believed to be largely phenomenology, increasing evidence shows that many of these dark proteins may have critical roles in human disease, from cancer to obesity, serving as ideal diagnostic biomarkers or therapeutic targets.? ?? As #massspectrometry methods are advancing to detect these protein variants, a more comprehensive exploration of the dark proteome is now finally possible. At Sapient, we provide the deep expertise and state-of-the-art approaches required for interrogation and analysis of the non-canonical dark proteome.?? ? ?? Read the full Science article: https://lnkd.in/g93qfKag ???Explore Sapient's services at https://lnkd.in/gp-QVpQF

Enjoy this panel session from Oxford Global's ??????????-?????????? ???? ?????????????????? ?????????????????? & ?????????????????? ????????????????, held in November 2024. Sapient's Dr. Jonathan Usuka, Chief Business Officer, joins expert panelists from Boehringer Ingelheim, Arizona State University, The Institute of Cancer Research, London, and SciLifeLab to discuss overcoming the challenges of multi-omic data integration for biomarker discovery. These panelists share best practices for the implementation and harmonization of various multi-omic datasets – from leveraging AI to integrating real-world data to support biomarker validation – and discuss key strategies that are needed to improve large-scale data handling, #multiomic data accuracy, ML-based analysis, and more. Watch the panel video here: https://lnkd.in/gZWNMTu7

With the field of #multiomics evolving rapidly, particularly within the #proteomics space, you need ?????? ?????????????? to keep pace. Our last newsletter of the year will be dropping soon, so if you are not yet #subscribed be sure to sign up to receive this coming edition. It will be complete with content on the latest applications of protein, metabolite, and lipid #biomarkers to advance drug development, including key discoveries and examples of how both discovery and targeted approaches are progressing sponsors' programs. Subscribe today: https://lnkd.in/gzZbWxQ6 #TheINsight #discovermore

Mo Jain traded academia to found Sapient, using mass spectrometry and AI to advance drug discovery. From physician to professor to entrepreneur, Mo’s journey is all about innovation in life science. Learn more in our November Member Spotlight: https://bit.ly/3YX9tLR

As investment in and approvals for GLP-1 therapies continue to accelerate, sponsors must ensure their development efforts can keep pace. Discovery #metabolomics can provide an unprecedented view into metabolic changes induced by GLP-1 agonists, revealing #biomarkers can be applied for: ?? Deepening #GLP1 mechanistic insights? ?? Patient stratification in GLP-1 agonist #clinicaltrials ?? Safety profiling of GLP-1 therapy ?? Expansion of GLP-1 agonist indications Learn more about how nontargeted profiling of dynamic biomarkers can uncover novel biological insights that drive greater competitive advantages. https://lnkd.in/gRqn_DGD

#Multiomics innovation was on display last week at Oxford Global's Multi-Omics in Biomarker Discovery & Precision Medicine Online Symposium! We thank all the speakers and delegates that joined us to share how they are integrating multi-omics technologies and techniques into therapeutic R&D. If you weren't able to make the live symposium, you can still watch Sapient's feature session, presented by Dr. Jonathan Usuka, here: https://lnkd.in/gHFYrBwZ

We're #hiring a new Business Development/Sr Business Development Director in San Diego Metropolitan Area. Apply today or share this post with your network.

#Hiring: We are seeking a highly motivated, detail-oriented ???????????????? ?????????????????????? ???????????????? to join our growing commercial team. If you're interested in building?long-lasting client relationships by empowering pharma and biotech sponsors with actionable insight to advance their drug programs successfully, #apply today: https://lnkd.in/gejM6iD9 #careers #businessdevelopment #BD #SapientTeam

"There are diseases in which the #genome does change—cancer being the prime example, as there are mutations that occur. But what about other diseases for which the genome is not changing? Heart disease, GI illness, liver disease, immunology and inflammatory diseases, fibrotic diseases, neurodegenerative diseases and renal disease are all examples with limited genetic influence. How do we begin to interrogate that? That is the basis of Sapient going #beyondthegenome, being able to understand the dynamic #biomarkers that can read out a person’s health, future disease risk, what drugs they’re going to respond to. This is information we're trying to capture to complement their underlying genomic risk score." Read more from Mo Jain, MD PhD's recent interview with Biocom California discussing the exciting strides being made in #multiomics technology to allow for large-scale discovery of dynamic #biomarkers. See how these protein, metabolite, and lipid markers are being applied in precision medicine programs today: https://lnkd.in/gc-YvD-m